Frequency and predictors of colonization of the respiratory tract by VIM-2-producing Pseudomonas aeruginosa in patients of a newly established intensive care unit
The aim of this study was to examine the frequency and predictors of colonization of the respiratory tract by metallo-β-lactamase (MBL)-producing Gram-negative bacteria in patients admitted to a newly established intensive care unit (ICU) of a tertiary care hospital. Specimens of tracheobronchial aspirates for microbiological studies were obtained every day for the first 3 days of the ICU stay and subsequently every third day for the rest of the ICU stay. PCR analysis and nucleotide sequencing were performed to identify bacteria that had MBL genes. Thirty-five patients (20 male, 15 female) were hospitalized during the initial 3 month period of functioning of the ICU. Colonization of the lower respiratory tract by Gram-negative bacteria was found in 29 of 35 patients (83 %) during the first 6–20 days (median 13 days) following admission to the ICU (13 patients with Acinetobacter baumannii, ten with Pseudomonas aeruginosa, three with Enterobacter aerogenes, two with Klebsiella pneumoniae and one with Stenotrophomonas maltophilia). Six of 29 patients (21 %) colonized with Gram-negative bacteria had blaVIM-2-positive P. aeruginosa isolates; one of these patients developed clinical infection due to this micro-organism. Previous use of carbapenems (P=0.01) or other β-lactams (P=0.03), as well as a stay in the ICU of >20 days (P<0.001), were associated with colonization with blaVIM-2-producing P. aeruginosa. In conclusion, colonization by Gram-negative bacteria of the respiratory tract of patients in this newly established ICU was common (83 %). Use of β-lactams, including carbapenems, was associated with subsequent colonization of the respiratory tract with MBL-positive P. aeruginosa.
AndradeS. S.,
JonesR. N.,
GalesA. C.,
SaderH. S.2003; Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997–2001). J Antimicrob Chemother 52:140–141[CrossRef]
BontenM. J.,
WeinsteinR. A.1996; The role of colonization in the pathogenesis of nosocomial infections. Infect Control Hosp Epidemiol 17:193–200[CrossRef]
BontenM. J.,
GaillardC. A.,
van TielF. H.,
SmeetsH. G.,
van der GeestS.,
StobberinghE. E.1994; The stomach is not a source for colonization of the upper respiratory tract and pneumonia in ICU patients. Chest 105:878–884[CrossRef]
de ChampsC.,
PoirelL.,
BonnetR.,
SirotD.,
ChanalC.,
SirotJ.,
NordmannP.2002; Prospective survey of β -lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 46:3031–3034[CrossRef]
FlahertyJ. P.,
WeinsteinR. A.1996; Nosocomial infection caused by antibiotic-resistant organisms in the intensive care unit. Infect Control Hosp Epidemiol 17:236–248[CrossRef]
ItokazuG. S.,
QuinnJ. P.,
Bell-DixonC.,
KahanF. M.,
WeinsteinR. A.1996; Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis 23:779–784[CrossRef]
JarvisW. R.,
EdwardsJ. R.,
CulverD. H.8 other authors1991; Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Am J Med 91 (Suppl. 2):S185–S191[CrossRef]
JohansonW. G.Jr,
PierceA. K.,
SanfordJ. P.,
ThomasG. D.1972; Nosocomial respiratory infections with Gram-negative bacilli. The significance of colonization of the respiratory tract. Ann Intern Med 77:701–706[CrossRef]
KerverA. J.,
RommesJ. H.,
Mevissen-VerhageE. A.,
HulstaertP. F.,
VosA.,
VerhoefJ.,
WittebolP.1988; Prevention of colonization and infection in critically ill patients: a prospective randomized study. Crit Care Med 16:1087–1093[CrossRef]
Le GallJ. R.,
LemeshowS.,
SaulnierF.1993; A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA ( J Am Med Assoc ) 270:2957–2963[CrossRef]
PoirelL.,
NaasT.,
NicolasD.,
ColletL.,
BellaisS.,
CavalloJ.-D.,
NordmannP.2000; Characterization of VIM-2, a carbapenem-hydrolyzing metallo- β -lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 44:891–897[CrossRef]
PournarasS.,
TsakrisA.,
ManiatiM.,
TzouvelekisL. S.,
ManiatisA. N.2002; Novel variant ( bla VIM-4) of the metallo- β -lactamase gene bla VIM-1 in a clinical strain of Pseudomonas aeruginosa
. Antimicrob Agents Chemother 46:4026–4028[CrossRef]
TrautmannM.,
MichalskyT.,
WiedeckH.,
RadosavljevicV.,
RuhnkeM.2001; Tap water colonization with Pseudomonas aeruginosa in a surgical intensive care unit (ICU) and relation to Pseudomonas infections of ICU patients. Infect Control Hosp Epidemiol 22:49–52[CrossRef]
WoodsD. E.,
StrausD. C.,
JohansonW. G.Jr,
BassJ. A.1981; Role of fibronectin in the prevention of adherence of Pseudomonas aeruginosa to buccal cells. J Infect Dis 143:784–790[CrossRef]
YanJ.-J.,
HsuehP.-R.,
KoW.-C.,
LuhK.-T.,
TsaiS.-H.,
WuH.-M.,
WuJ. J.2001; Metallo- β ±-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 45:2224–2228[CrossRef]
Frequency and predictors of colonization of the respiratory tract by VIM-2-producing Pseudomonas aeruginosa in patients of a newly established intensive care unit